On the 29th, the MFDS approved 3 multi-national clinical plans for "PF-07321332," a candidate for COVID-19 oral treatment applied by Pfizer.

The first clinical trial was the oral administration of PF-07321332 to prevent postmortem infections in adults who had contact with people with COVID-19, and the validity and safety of Ritonavir's two methods. The total number of test subjects is 2,634 and 22 people will be recruited in Korea. The test is conducted at Chilgok Kyungbuk National University Hospital.

The second clinical trial assesses the mediated validity and safety of oral administration PF-07321332/Ritonavir in comparison to placebo in non-admission-bearing adult participants with s